secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001104659-23-037376
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics enters Novartis collaboration for Bicycle radio-conjugates; $50M upfront, up to $1.7B milestones
--------------------------------------------------------------------------------

- Bicycle Therapeutics receives $50M upfront from Novartis to discover Bicycle radio-conjugates for oncology targets.
- Total potential milestones up to $1.7B, plus tiered royalties on commercial sales at high single to low double digits.
- Novartis funds all preclinical/clinical development, manufacturing, and commercialization for BRCs.
- Collaboration initially covers two targets; Novartis pays mid-teen million candidate selection fees per product.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465923037376/0001104659-23-037376-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465923037376/tm2310706d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-037376

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer